Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema

CompletedOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

June 29, 2024

Study Completion Date

July 30, 2024

Conditions
Age Related Macular DegenerationDiabetic Macular Edema
Interventions
DRUG

Intravitreal Aflibercept Injection

After instillation of topical anesthesia (0.4% oxybuprocaine hydrochloride and lidocain; own production), sterilization of the eyelid (Betaisodona solution 11% povidone-iodine, Mundipharma, Limburg, Germany), and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) will be injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions.

DEVICE

Laser speckle flowgraphy

"The RetFlow consists of a fundus camera equipped with a diode laser at a wavelength of 830 nm and a digital charge-coupled device camera (750 x 360 pixels). A total of 118 images are acquired at a rate of 30 frames per second over a 4-second measurement period. The main output parameter of LSFG, mean blur rate (MBR), is calculated from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. MBR was calculated for the total ONH area, defined by a ellipsoid region of interest (ROI). By using the on-board software, the MBR will be calculated in the large vessels within the ONH (ONH-MV, mean MBR of vascular area) and the tissue area containing the microvasculature (ONH-MT, mean MBR of tissue area)"

Trial Locations (1)

4020

Department for Ophthalmology, Linz

All Listed Sponsors
lead

Augenabteilung Allgemeines Krankenhaus Linz

OTHER

NCT06878573 - Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema | Biotech Hunter | Biotech Hunter